Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Siobhan Calafiore, Senior Journalist at the limbic, shared a post on LinkedIn about a recent article she authored, published in The Limbic:
“This week I reported on the landmark COBRRA trial addressing one of the common clinical dilemmas for haematologists treating community-acquired blood clots, ‘which anticoagulant do I give my patient?’
For years, clinical guidelines have been unable to preference one DOAC over the other due to a complete lack of head-to-head trials.
The latest findings suggest while both DOACs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, more than halving the risk of bleeding.
Australia had a big role to play in this practice-changing study and I was lucky enough to chat to Australia’s lead investigator Vivien Chen about the practical difference these findings will make in everyday practice around the world. ”
Title: Landmark VTE trial backs apixaban over rivaroxaban
Authors: Siobhan Calafiore
Read the Full Article on The Limbic
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 21, 2026, 03:00Family History Can Reveal Hidden Risk of Aortic Dissection – The Marfan Foundation
-
Sep 21, 2026, 02:47Transitioning from Paediatric to Adult Haemophilia Care – Haemophilia Foundation Australia
-
Sep 21, 2026, 02:29Diana Castro Paupério: A New Era for Patient Blood Management
-
Sep 21, 2026, 00:29Iheanyichukwu Ike: Childhood Anaemia in Nigeria Through an Analysis of the 2018 NDHS
-
Sep 21, 2026, 00:27Nicole De Vita: The Global Burden of Iron Deficiency and Anemia in Women at SABM
-
Sep 21, 2026, 00:25Giuseppe Panuccio: IVUS and OCT Guidance Reduce MACE and Stent Thrombosis in Calcified Coronary Lesions
-
Sep 21, 2026, 00:23Parveen Yograj: Anemia in Older Adults 2026 – Don’t Call It “Just Old Age” and Find the Cause
-
Sep 21, 2026, 00:22Peter A. McCullough: McCullough Protocol Base Spike Detoxification and Oral Anticoagulation for Athletes
-
Sep 21, 2026, 00:20Rolando Claure: Apixaban Shows a More Favorable Benefit Risk Balance in Advanced CKD With AF